2022
The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice
Ullah I, Beaudoin-Bussières G, Symmes K, Cloutier M, Ducas E, Tauzin A, Laumaea A, Grunst M, Dionne K, Richard J, Bégin P, Mothes W, Kumar P, Bazin R, Finzi A, Uchil P. The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice. Cell Reports Medicine 2022, 4: 100893. PMID: 36584683, PMCID: PMC9799175, DOI: 10.1016/j.xcrm.2022.100893.Peer-Reviewed Original ResearchConceptsCOVID-19 convalescent plasmaFc effector functionsSARS-CoV-2 controlFc effector activityInnate immune cellsCCP efficacyHACE2 miceConvalescent plasmaImmunoglobulin levelsPlasma therapyImmune cellsTreatment efficacyDelays mortalityIgG fractionFc functionLow neutralizingTherapySecond lineMortalityMicePlasma contributesEfficacyFC activityProphylaxisIgG
2013
Cell-to-Cell Transmission of HIV
Agosto L, Zhong P, Mothes W. Cell-to-Cell Transmission of HIV. 2013, 167-184. DOI: 10.1007/978-1-4614-7729-7_7.Peer-Reviewed Original ResearchCell-free virusAnti-retroviral therapyCell-free HIVCell transmissionHIV/AIDSHIV cellDifferent lymphocytesVirological synapseVirological synapsesHIVCell-free spreadImmunological synapsesTarget cellsRestriction factorsHIV assemblySynapsesVirusCellsCell-cell contactSynapse modelLymphocytesPathogenesisTherapyAIDSAntibodies